ES2765489T3 - Adenovirus que expresa agonista(s) del receptor estimulante de células inmunitarias - Google Patents
Adenovirus que expresa agonista(s) del receptor estimulante de células inmunitarias Download PDFInfo
- Publication number
- ES2765489T3 ES2765489T3 ES14864921T ES14864921T ES2765489T3 ES 2765489 T3 ES2765489 T3 ES 2765489T3 ES 14864921 T ES14864921 T ES 14864921T ES 14864921 T ES14864921 T ES 14864921T ES 2765489 T3 ES2765489 T3 ES 2765489T3
- Authority
- ES
- Spain
- Prior art keywords
- adenovirus
- cancer
- nucleic acid
- cells
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 127
- 239000000018 receptor agonist Substances 0.000 title description 37
- 229940044601 receptor agonist Drugs 0.000 title description 37
- 230000010076 replication Effects 0.000 claims abstract description 91
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 74
- 244000309459 oncolytic virus Species 0.000 claims abstract description 69
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 60
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 60
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims abstract description 56
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims abstract description 49
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims abstract description 47
- 239000000556 agonist Substances 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 101710125418 Major capsid protein Proteins 0.000 claims abstract description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 11
- 239000003446 ligand Substances 0.000 claims abstract description 10
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims abstract description 6
- 229920001184 polypeptide Polymers 0.000 claims abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 124
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 201000011510 cancer Diseases 0.000 claims description 44
- 230000000174 oncolytic effect Effects 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 206010018338 Glioma Diseases 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 230000002163 immunogen Effects 0.000 claims description 18
- 208000032612 Glial tumor Diseases 0.000 claims description 17
- 239000002269 analeptic agent Substances 0.000 claims description 15
- 201000001441 melanoma Diseases 0.000 claims description 15
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 10
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 9
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 9
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 9
- -1 IL13Ralpha Proteins 0.000 claims description 8
- 108090000978 Interleukin-4 Proteins 0.000 claims description 8
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 7
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229960004964 temozolomide Drugs 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 7
- 229960000473 altretamine Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960004961 mechlorethamine Drugs 0.000 claims description 6
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 6
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- 241000598171 Human adenovirus sp. Species 0.000 claims description 5
- 102100021906 Cyclin-O Human genes 0.000 claims description 4
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 229960002092 busulfan Drugs 0.000 claims description 4
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims description 3
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims description 3
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims description 3
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 3
- OUUYBRCCFUEMLH-YDALLXLXSA-N [(1s)-2-[4-[bis(2-chloroethyl)amino]phenyl]-1-carboxyethyl]azanium;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 OUUYBRCCFUEMLH-YDALLXLXSA-N 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 190000008236 carboplatin Chemical compound 0.000 claims description 3
- 229960004630 chlorambucil Drugs 0.000 claims description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960001101 ifosfamide Drugs 0.000 claims description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 229960002247 lomustine Drugs 0.000 claims description 3
- 229960002514 melphalan hydrochloride Drugs 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001196 thiotepa Drugs 0.000 claims description 3
- 229950007217 tremelimumab Drugs 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 101150104494 CAV1 gene Proteins 0.000 claims description 2
- 102000000905 Cadherin Human genes 0.000 claims description 2
- 108050007957 Cadherin Proteins 0.000 claims description 2
- 102000004225 Cathepsin B Human genes 0.000 claims description 2
- 108090000712 Cathepsin B Proteins 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 2
- 102100039717 G antigen 1 Human genes 0.000 claims description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 claims description 2
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 2
- 101001069749 Homo sapiens Prospero homeobox protein 1 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 claims description 2
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 claims description 2
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 claims description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims description 2
- 101000836268 Homo sapiens U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 101150038998 PLAUR gene Proteins 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 102100033880 Prospero homeobox protein 1 Human genes 0.000 claims description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 claims description 2
- 102100038808 Transcription factor SOX-10 Human genes 0.000 claims description 2
- 102100022415 Transcription factor SOX-11 Human genes 0.000 claims description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims description 2
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 claims description 2
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 229950010773 pidilizumab Drugs 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
- 229960001052 streptozocin Drugs 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- APHFXDBDLKPMTA-UHFFFAOYSA-N 2-(3-decanoyl-4,5,7-trihydroxynaphthalen-2-yl)acetic acid Chemical compound CCCCCCCCCC(=O)c1c(CC(O)=O)cc2cc(O)cc(O)c2c1O APHFXDBDLKPMTA-UHFFFAOYSA-N 0.000 claims 1
- OCNCNSYDNQAFGM-UHFFFAOYSA-N 3,4-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound NP1(=O)OCCC(CCCl)N1CCCl OCNCNSYDNQAFGM-UHFFFAOYSA-N 0.000 claims 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
- 102100033680 Bombesin receptor-activated protein C6orf89 Human genes 0.000 claims 1
- 101150012716 CDK1 gene Proteins 0.000 claims 1
- 102100026548 Caspase-8 Human genes 0.000 claims 1
- 108090000538 Caspase-8 Proteins 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 102100038281 Cytospin-A Human genes 0.000 claims 1
- 101150005585 E3 gene Proteins 0.000 claims 1
- 102100024405 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Human genes 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 102100034153 Golgin subfamily A member 6B Human genes 0.000 claims 1
- 102100031624 Heat shock protein 105 kDa Human genes 0.000 claims 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
- 101000984746 Homo sapiens BRCA1-associated protein Proteins 0.000 claims 1
- 101000944524 Homo sapiens Bombesin receptor-activated protein C6orf89 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 1
- 101000884816 Homo sapiens Cytospin-A Proteins 0.000 claims 1
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 claims 1
- 101100449143 Homo sapiens GOLGA6B gene Proteins 0.000 claims 1
- 101000981252 Homo sapiens GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000866478 Homo sapiens Heat shock protein 105 kDa Proteins 0.000 claims 1
- 101001001418 Homo sapiens Inhibitor of growth protein 4 Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101000979578 Homo sapiens NK-tumor recognition protein Proteins 0.000 claims 1
- 101000801664 Homo sapiens Nucleoprotein TPR Proteins 0.000 claims 1
- 101100029612 Homo sapiens PHF20 gene Proteins 0.000 claims 1
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 claims 1
- 101000872170 Homo sapiens Polycomb complex protein BMI-1 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101000583459 Homo sapiens Progesterone-induced-blocking factor 1 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 claims 1
- 101000727472 Homo sapiens Reticulon-4 Proteins 0.000 claims 1
- 101000823796 Homo sapiens Y-box-binding protein 1 Proteins 0.000 claims 1
- 102100035677 Inhibitor of growth protein 4 Human genes 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 108010092801 Midkine Proteins 0.000 claims 1
- 102000016776 Midkine Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 102100023384 NK-tumor recognition protein Human genes 0.000 claims 1
- 102100033615 Nucleoprotein TPR Human genes 0.000 claims 1
- 102100036878 PHD finger protein 20 Human genes 0.000 claims 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 claims 1
- 102100033566 Polycomb complex protein BMI-1 Human genes 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100031015 Progesterone-induced-blocking factor 1 Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 claims 1
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 claims 1
- 102100029831 Reticulon-4 Human genes 0.000 claims 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 1
- 101150006914 TRP1 gene Proteins 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 102100022224 Y-box-binding protein 1 Human genes 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 108010066416 multidrug resistance-associated protein 3 Proteins 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims 1
- 102000016914 ras Proteins Human genes 0.000 claims 1
- 108010014186 ras Proteins Proteins 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 abstract description 43
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 124
- 241000700605 Viruses Species 0.000 description 45
- 230000014509 gene expression Effects 0.000 description 45
- 241000699670 Mus sp. Species 0.000 description 29
- 210000001744 T-lymphocyte Anatomy 0.000 description 25
- 238000000034 method Methods 0.000 description 25
- 238000011282 treatment Methods 0.000 description 24
- 210000004881 tumor cell Anatomy 0.000 description 23
- 239000003623 enhancer Substances 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 210000002865 immune cell Anatomy 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000003612 virological effect Effects 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 230000004936 stimulating effect Effects 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- 210000003289 regulatory T cell Anatomy 0.000 description 14
- 210000004988 splenocyte Anatomy 0.000 description 14
- 238000002513 implantation Methods 0.000 description 13
- 241000701022 Cytomegalovirus Species 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 102000008096 B7-H1 Antigen Human genes 0.000 description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 241001135569 Human adenovirus 5 Species 0.000 description 8
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 108700010013 HMGB1 Proteins 0.000 description 7
- 101150021904 HMGB1 gene Proteins 0.000 description 7
- 102100037907 High mobility group protein B1 Human genes 0.000 description 7
- 102000015696 Interleukins Human genes 0.000 description 7
- 108010063738 Interleukins Proteins 0.000 description 7
- 101000764258 Mus musculus Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 7
- 229940124060 PD-1 antagonist Drugs 0.000 description 7
- 229940123751 PD-L1 antagonist Drugs 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 108010082808 4-1BB Ligand Proteins 0.000 description 6
- 102000002627 4-1BB Ligand Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000005975 antitumor immune response Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000711404 Avian avulavirus 1 Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 description 4
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 241000714474 Rous sarcoma virus Species 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000005809 anti-tumor immunity Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000002644 phorbol ester Substances 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 239000012130 whole-cell lysate Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010014967 Ependymoma Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101710145505 Fiber protein Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101710113864 Heat shock protein 90 Proteins 0.000 description 3
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000029662 T-helper 1 type immune response Effects 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001348 anti-glioma Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000051450 human TNFSF4 Human genes 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 206010001258 Adenoviral infections Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 101710199711 Early E1A protein Proteins 0.000 description 2
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 2
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 101150112743 HSPA5 gene Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101000833614 Homo sapiens Interferon-inducible protein AIM2 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 2
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 2
- 101710204288 Melanoma-associated antigen 3 Proteins 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 2
- 101100153537 Mus musculus Tnfrsf4 gene Proteins 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000007584 Prealbumin Human genes 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108050002653 Retinoblastoma protein Proteins 0.000 description 2
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 108010017007 glucose-regulated proteins Proteins 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 101150028578 grp78 gene Proteins 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 102000047582 human L1CAM Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 102000004233 multidrug resistance protein 3 Human genes 0.000 description 2
- 108090000743 multidrug resistance protein 3 Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- VVJYUAYZJAKGRQ-BGZDPUMWSA-N 1-[(2r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)C1 VVJYUAYZJAKGRQ-BGZDPUMWSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 241001533362 Astroviridae Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 1
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 241000701412 Baculoviridae Species 0.000 description 1
- 241001533460 Barnaviridae Species 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229940123205 CD28 agonist Drugs 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000520666 Carmotetraviridae Species 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 102100035888 Caveolin-1 Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000701520 Corticoviridae Species 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 101000667272 Dictyostelium discoideum Homeobox protein Wariai Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 101710114676 E1B 55 kDa protein Proteins 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000701367 Fuselloviridae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 101710103773 Histone H2B Proteins 0.000 description 1
- 102100021639 Histone H2B type 1-K Human genes 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 101000804921 Homo sapiens X-ray repair cross-complementing protein 5 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000702394 Inoviridae Species 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 241000701365 Lipothrixviridae Species 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 206010025652 Malignant melanoma in situ Diseases 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 101710201349 Metallothionein B Proteins 0.000 description 1
- 102100031347 Metallothionein-2 Human genes 0.000 description 1
- 101710094505 Metallothionein-2 Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241000702318 Microviridae Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001074047 Mus musculus Zinc finger protein GLI1 Proteins 0.000 description 1
- 241000701553 Myoviridae Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000723741 Nodaviridae Species 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000701253 Phycodnaviridae Species 0.000 description 1
- 241000701369 Plasmaviridae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000701374 Polydnaviridae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000702202 Siphoviridae Species 0.000 description 1
- 235000019892 Stellar Nutrition 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241001533336 Tombusviridae Species 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- VRGWBRLULZUWAJ-XFFXIZSCSA-N [(2s)-2-[(1r,3z,5s,8z,12z,15s)-5,17-dihydroxy-4,8,12,15-tetramethyl-16-oxo-18-bicyclo[13.3.0]octadeca-3,8,12,17-tetraenyl]propyl] acetate Chemical compound C1\C=C(C)/CC\C=C(C)/CC[C@H](O)\C(C)=C/C[C@@H]2C([C@@H](COC(C)=O)C)=C(O)C(=O)[C@]21C VRGWBRLULZUWAJ-XFFXIZSCSA-N 0.000 description 1
- ZMJPCIAEJKVKMQ-UHFFFAOYSA-M [4-[[4-[benzyl(methyl)amino]phenyl]-[4-(dimethylamino)phenyl]methylidene]cyclohexa-2,5-dien-1-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)N(C)CC=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 ZMJPCIAEJKVKMQ-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 108010084938 adenovirus receptor Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 201000008719 cranial nerve neoplasm Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 208000014616 embryonal neoplasm Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- VRGWBRLULZUWAJ-UHFFFAOYSA-N fusaproliferin Natural products C1C=C(C)CCC=C(C)CCC(O)C(C)=CCC2C(C(COC(C)=O)C)=C(O)C(=O)C21C VRGWBRLULZUWAJ-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000026436 grade III glioma Diseases 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000054189 human CD80 Human genes 0.000 description 1
- 102000043283 human SERPINE1 Human genes 0.000 description 1
- 102000053830 human TNFSF18 Human genes 0.000 description 1
- 102000047299 human XRCC5 Human genes 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000011575 immunodeficient mouse model Methods 0.000 description 1
- 230000037449 immunogenic cell death Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004479 myeloid suppressor cell Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 208000016359 neuroblastic tumor Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229930185346 proliferin Natural products 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907860P | 2013-11-22 | 2013-11-22 | |
| PCT/US2014/066920 WO2015077624A1 (en) | 2013-11-22 | 2014-11-21 | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2765489T3 true ES2765489T3 (es) | 2020-06-09 |
Family
ID=53180213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14864921T Active ES2765489T3 (es) | 2013-11-22 | 2014-11-21 | Adenovirus que expresa agonista(s) del receptor estimulante de células inmunitarias |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20160289645A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3653714A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2016540505A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160137946A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114317461A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014352749A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2931322A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3071697T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2765489T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG10201907841UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015077624A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4663241A2 (en) | 2010-10-08 | 2025-12-17 | Mesoblast International Sàrl | Enhanced msc preparations |
| AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| NO3021859T3 (cg-RX-API-DMAC7.html) | 2013-10-25 | 2018-04-28 | ||
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| KR20170109582A (ko) * | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| EA037611B1 (ru) | 2015-04-30 | 2021-04-21 | Псайоксус Терапьютикс Лимитед | Онколитический аденовирус, кодирующий белок b7 |
| TWI716405B (zh) | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
| ES2994611T3 (en) * | 2015-10-19 | 2025-01-27 | Cg Oncology Inc | Methods of treating solid or lymphatic tumors by combination therapy |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| WO2017103291A1 (en) | 2015-12-17 | 2017-06-22 | Psioxus Therapeutics Limited | Virus encoding an anti-tcr-complex antibody or fragment |
| CN109415703B (zh) | 2016-01-08 | 2024-08-30 | 雷普利穆内有限公司 | 经修饰的溶瘤病毒 |
| ES2933174T3 (es) | 2016-02-23 | 2023-02-02 | Salk Inst For Biological Studi | Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral |
| CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| JP7208492B2 (ja) | 2016-03-10 | 2023-01-19 | シージー オンコロジー， インコーポレイテッド | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| EP3463405A4 (en) * | 2016-05-27 | 2020-02-26 | DNAtrix, Inc. | Adenovirus and immunomodulator combination therapy |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| SG11201901716TA (en) | 2016-08-29 | 2019-03-28 | Psioxus Therapeutics Ltd | Adenovirus armed with bispecific t cell engager (bite) |
| HUE053236T2 (hu) | 2016-09-12 | 2021-06-28 | Targovax Oy | Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| WO2018111902A1 (en) * | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| US11298420B2 (en) * | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| AU2017379835A1 (en) | 2016-12-21 | 2019-07-11 | Dnatrix | Armed replication-competent oncolytic adenoviruses |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CN108338994A (zh) | 2017-01-25 | 2018-07-31 | 杭州康万达医药科技有限公司 | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 |
| CA3058938A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
| EP4599893A3 (en) | 2017-04-14 | 2025-11-05 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
| CN109276580B (zh) | 2017-07-21 | 2021-08-24 | 厦门大学 | 一种用于治疗肿瘤的病毒 |
| KR102776166B1 (ko) | 2017-08-07 | 2025-03-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
| CN112004923A (zh) | 2017-11-22 | 2020-11-27 | 迈索布拉斯特国际有限公司 | 细胞组合物及治疗方法 |
| CN107952069A (zh) * | 2017-11-24 | 2018-04-24 | 长春百克生物科技股份公司 | 重组疫苗及其应用 |
| CN109985241B (zh) * | 2017-12-29 | 2024-10-18 | 广州威溶特医药科技有限公司 | Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| CN112020510B (zh) | 2018-03-19 | 2024-10-11 | 茂体外尔公司 | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 |
| WO2019191494A1 (en) * | 2018-03-28 | 2019-10-03 | Epicentrx, Inc. | Personalized cancer vaccines |
| EP3775175A4 (en) | 2018-04-09 | 2022-02-09 | Salk Institute for Biological Studies | ONCOLYTIC ADENOVIRUS COMPOSITIONS WITH IMPROVED REPLICATION PROPERTIES |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| JP7480126B2 (ja) * | 2018-09-15 | 2024-05-09 | メモリアル スローン ケタリング キャンサー センター | がん免疫療法のための、組換えポックスウイルス |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020172509A1 (en) * | 2019-02-21 | 2020-08-27 | Unleash Immuno Oncolytics, Inc. | Oncolytic adenoviral vector and methods of use |
| CN114423860A (zh) | 2019-08-05 | 2022-04-29 | 迈索布拉斯特国际有限公司 | 包含病毒载体的细胞组合物及治疗方法 |
| MX2022005980A (es) | 2019-11-18 | 2022-09-07 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos. |
| CN110859968A (zh) * | 2019-11-21 | 2020-03-06 | 四川安可康生物医药有限公司 | 激活对肿瘤的系统免疫反应的基因生物药物 |
| KR20220152250A (ko) * | 2020-03-06 | 2022-11-15 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 암을 치료하기 위한 irf 모듈레이터를 발현하는 종양용해성 바이러스 |
| WO2021252496A1 (en) * | 2020-06-10 | 2021-12-16 | Richard Lowenthal | Engineered adenovirus vectors and uses thereof |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| KR20230046298A (ko) | 2020-08-10 | 2023-04-05 | 메조블라스트 인터내셔널 에스에이알엘 | 세포 조성물 및 치료 방법 |
| JP7614980B2 (ja) | 2021-08-25 | 2025-01-16 | 三菱重工航空エンジン株式会社 | 燃焼器パネル、及びガスタービン用燃焼器 |
| WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| JPH11503910A (ja) | 1995-04-17 | 1999-04-06 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | アデノウイルスヘルパーウイルスシステム |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| EP1044263A2 (en) * | 1997-12-02 | 2000-10-18 | Medarex, Inc. | CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| US7368527B2 (en) * | 1999-03-12 | 2008-05-06 | Human Genome Sciences, Inc. | HADDE71 polypeptides |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| EP1470233A1 (en) * | 2002-02-01 | 2004-10-27 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with pods |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| NZ536746A (en) | 2002-06-13 | 2007-02-23 | Crucell Holland Bv | An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| KR101531400B1 (ko) | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| JP2008531481A (ja) * | 2005-02-08 | 2008-08-14 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | 癌の治療のための、ｍｄａ−７を含む組成物および方法 |
| PT1877090E (pt) | 2005-05-06 | 2014-04-15 | Providence Health System | Proteína de fusão trimérica de imunoglobulina-ox40 e métodos de utilização |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| ES2304281B1 (es) * | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| EP2133365B1 (en) | 2006-12-27 | 2017-05-17 | Emory University | Compositions and methods for the treatment of infections and tumors |
| EP2328919A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| BRPI0920679A2 (pt) * | 2008-10-08 | 2022-05-17 | Intrexon Corp | Células construídas expressando múltiplos imunomoduladores e usos das mesmas |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| ES2630328T3 (es) * | 2010-08-23 | 2017-08-21 | Board Of Regents, The University Of Texas System | Anticuerpos anti-OX40 y procedimientos de uso de los mismos |
| CA2812096A1 (en) * | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Adenoviral vectors and methods and uses related thereto |
| EP2675933B1 (en) * | 2011-02-17 | 2017-02-08 | Alcoa Inc. | 2xxx series aluminum lithium alloys |
| CN104093830A (zh) * | 2011-04-15 | 2014-10-08 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| WO2013112942A1 (en) * | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| SG10201606356YA (en) * | 2012-02-02 | 2016-09-29 | Univ Texas | Adenoviruses expressing heterologous tumor-associated antigens |
-
2014
- 2014-11-21 AU AU2014352749A patent/AU2014352749A1/en not_active Abandoned
- 2014-11-21 WO PCT/US2014/066920 patent/WO2015077624A1/en not_active Ceased
- 2014-11-21 CN CN202111419932.6A patent/CN114317461A/zh active Pending
- 2014-11-21 CA CA2931322A patent/CA2931322A1/en not_active Abandoned
- 2014-11-21 JP JP2016533143A patent/JP2016540505A/ja not_active Withdrawn
- 2014-11-21 EP EP19203386.8A patent/EP3653714A1/en not_active Withdrawn
- 2014-11-21 EP EP14864921.3A patent/EP3071697B1/en active Active
- 2014-11-21 KR KR1020167016399A patent/KR20160137946A/ko not_active Ceased
- 2014-11-21 SG SG10201907841U patent/SG10201907841UA/en unknown
- 2014-11-21 CN CN201480073813.1A patent/CN106029889A/zh active Pending
- 2014-11-21 ES ES14864921T patent/ES2765489T3/es active Active
- 2014-11-21 US US15/038,446 patent/US20160289645A1/en not_active Abandoned
- 2014-11-21 DK DK14864921.3T patent/DK3071697T3/da active
-
2018
- 2018-06-27 US US16/020,738 patent/US20190093085A1/en not_active Abandoned
-
2019
- 2019-12-27 JP JP2019238013A patent/JP2020048582A/ja active Pending
-
2021
- 2021-06-11 US US17/304,006 patent/US20210301264A1/en not_active Abandoned
- 2021-06-11 JP JP2021097883A patent/JP2021137029A/ja active Pending
-
2024
- 2024-10-10 US US18/912,157 patent/US20250171745A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016540505A (ja) | 2016-12-28 |
| EP3071697A1 (en) | 2016-09-28 |
| CN106029889A (zh) | 2016-10-12 |
| CN114317461A (zh) | 2022-04-12 |
| AU2014352749A1 (en) | 2016-06-09 |
| EP3071697A4 (en) | 2017-05-17 |
| EP3653714A1 (en) | 2020-05-20 |
| US20160289645A1 (en) | 2016-10-06 |
| JP2021137029A (ja) | 2021-09-16 |
| US20190093085A1 (en) | 2019-03-28 |
| US20250171745A1 (en) | 2025-05-29 |
| EP3071697B1 (en) | 2019-10-16 |
| US20210301264A1 (en) | 2021-09-30 |
| DK3071697T3 (da) | 2020-01-27 |
| KR20160137946A (ko) | 2016-12-02 |
| SG10201907841UA (en) | 2019-10-30 |
| CA2931322A1 (en) | 2015-05-28 |
| JP2020048582A (ja) | 2020-04-02 |
| WO2015077624A1 (en) | 2015-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2765489T3 (es) | Adenovirus que expresa agonista(s) del receptor estimulante de células inmunitarias | |
| US11090344B2 (en) | Adenovirus and immunomodulator combination therapy | |
| ES2759785T3 (es) | Adenovirus que expresan antígenos oncógenos heterólogos | |
| ES2848064T3 (es) | Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas | |
| ES2971065T3 (es) | Terapia de combinación de virus vaccinia oncolítica y un inhibidor de punto de control | |
| US20150250837A1 (en) | Oncolytic virus encoding pd-1 binding agents and uses of the same | |
| CN111201035A (zh) | Il-2超激动剂、激动剂及其融合体的用途和方法 | |
| BR112021003644A2 (pt) | vacina para uso na profilaxia e/ou tratamento de uma doença | |
| KR20220116191A (ko) | 4-1bbl 아쥬반트화 재조합 변형 백시니아 바이러스 앙카라 (mva)의 의약적 용도 | |
| WO2022262764A1 (zh) | 一种基于lox1构建的嵌合抗原受体免疫细胞制备及其应用 | |
| US20250064873A1 (en) | TNFSF-L Fusion Proteins and Uses Thereof | |
| US20250009797A1 (en) | Methods and materials for treating cancer | |
| HK40030022A (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| WO2007068772A1 (es) | Nuevos adenovirus recombinantes de replicacion condicionada (crad) | |
| HK1230236A1 (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| US20220211814A1 (en) | Il-36 cytokine expressing oncolytic viruses for treating cancer | |
| HK40007925A (en) | Adenovirus and immunomodulator combination therapy | |
| WO2022262765A1 (zh) | 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用 | |
| WO2022011651A1 (zh) | 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法 | |
| Springer et al. | 707. Characterization of the Complex Physiological Response to Constitutive VEGF Gene Expression | |
| HK1223402B (zh) | 免疫溶瘤療法 |